A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

Trial ID or NCT#

NCT04505722

Status

not recruiting iconNOT RECRUITING

Purpose

The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.

Official Title

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Show Less

Investigator(s)

Philip Grant
Philip Grant
Positive care doctor, Infectious diseases doctor

View on ClinicalTrials.gov